Spectrum Pharma rises on FDA approval of neutropenia injection
09/09/2022 22:16
** Spectrum Pharmaceuticals' shares SPPI.O rise ~15% to
$1.45 in extended trading
** U.S. FDA has approved co's injection to decrease
incidence of neutropenia or low white blood cells in cancer
patients receiving myelosuppressive treatment like chemotherapy
and radiation urn:newsml:reuters.com:*:nBw8YxKH3a
** Co expects product to be available in Q4
** As of last close, stock was up ~2% YTD compared with a
~13.68% decline in the Nasdaq Biotechnology index .NBI
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary